Provided by Tiger Fintech (Singapore) Pte. Ltd.

HUTCHMED

23.500
+0.1500.64%
Volume:3.05M
Turnover:72.12M
Market Cap:20.49B
PE:68.67
High:24.100
Open:23.550
Low:23.350
Close:23.350
Loading ...

Innovent and HUTCHMED Jointly Announce Nmpa Conditional Approval for Tyvyt® (Sintilimab Injection) in Combination With Elunate® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

THOMSON REUTERS
·
04 Dec 2024

Hutchmed, Іnnovent Biologics Combination Injection Receives Conditional Approval in China

MT Newswires Live
·
03 Dec 2024

HUTCHMED, Innovent Get Conditional Approval in China for ELUNATE With TYVYT to Treat Advanced Endometrial Cancer

MT Newswires Live
·
03 Dec 2024

HUTCHMED (China) Ltd - Phase Iii Confirmatory Study Planned for Fruquintinib and Sintilimab

THOMSON REUTERS
·
03 Dec 2024

- HUTCHMED China Ltd - HUTCHMED and Innovent Announce Elunate Approval

THOMSON REUTERS
·
03 Dec 2024

HUTCHMED and Innovent Jointly Announce Nmpa Conditional Approval for Elunate® (Fruquintinib) in Combination With Tyvyt® (Sintilimab Injection) for the Treatment of Advanced Endometrial Cancer

THOMSON REUTERS
·
03 Dec 2024

Hutchmed's Lung Cancer Drug to Remain in China's National Reimbursement Drug List

MT Newswires Live
·
28 Nov 2024

HUTCHMED (China) Ltd - Announces Orpathys to Remain on China's Nrdl in 2025

THOMSON REUTERS
·
28 Nov 2024

HUTCHMED Announces Continued Inclusion of Orpathys® (Savolitinib) in the National Reimbursement Drug List in China at Current Terms

THOMSON REUTERS
·
28 Nov 2024

HUTCHMED Announces Continued Inclusion of ORPATHYS® (savolitinib) in the National Reimbursement Drug List in China at Current Terms

GlobeNewswire
·
28 Nov 2024

Kotra Industries Bhd Malaysia 1st-Quarter 2024 Earnings Summary Table

Dow Jones
·
27 Nov 2024

BRIEF-HUTCHMED Announces Launch By Takeda Of Fruzaqla® (Fruquintinib) In Japan

Reuters
·
22 Nov 2024

HUTCHMED Announces Launch by Takeda of Fruzaqla® (Fruquintinib) in Japan

THOMSON REUTERS
·
22 Nov 2024

Hutchmed to Receive Milestone Payment for Takeda's Fruzaqla Launch in Japan

MT Newswires Live
·
22 Nov 2024

HUTCHMED (China) To Launch Oral CRC Drug in Japan with Takeda; Shares Slide 3%

MT Newswires Live
·
22 Nov 2024

Press Release: HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

Dow Jones
·
20 Nov 2024

- HUTCHMED China Ltd - Clinical Data to Be Presented at Ash and Esmo Asia

THOMSON REUTERS
·
06 Nov 2024

HUTCHMED Highlights Clinical Data to be Presented at the 2024 ASH Annual Meeting and the 2024 ESMO Asia Congress

GlobeNewswire
·
06 Nov 2024

HUTCHMED Earns $20 Million Milestone Payment After Takeda Reaches Over $200 Million in Fruquintinib Sales

MT Newswires Live
·
31 Oct 2024

HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in Fruzaqla® (Fruquintinib) Sales by Takeda

THOMSON REUTERS
·
31 Oct 2024